While major indices hold steady, a search for growth is turning the spotlight onto smaller companies. We examine three small-cap stocks—from insurance to banking to luxury watches—that are posting strong results and navigating unique challenges in the current market.
Doctors Without Borders (MSF) has definitively rejected an Israeli order to hand over sensitive staff information, following months of failed negotiations. The move comes amid a wider crackdown on aid groups and a devastating toll on healthcare workers in the conflict.
Planet Labs secures a strategic enterprise agreement with the Slovenian government, expanding its public sector footprint with applications in agriculture, urban development, and disaster preparedness. The deal comes as investors scrutinize the company's premium market valuation amidst growing competition in the Earth observation sector.
SanDisk's stock surged after the data storage giant issued a blockbuster third-quarter outlook, far exceeding Wall Street expectations. The company credited soaring demand from artificial intelligence applications and announced a major extension to a key supply agreement, highlighting the intense competition for memory chips in the AI era.
Equifax is expanding beyond traditional credit reporting with a new suite of AI-powered fraud detection and income verification tools. While this strategic push aims to embed the company deeper into the lending ecosystem, analysts remain divided on whether it's enough to support its current valuation amid high debt and execution risks.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Taiwan Semiconductor Manufacturing Company (TSMC) reaches unprecedented market valuation following robust quarterly earnings, driven by insatiable demand for advanced AI chips. Analysts weigh whether the rally still has room to run.
Western Digital's fiscal Q2 2026 results showcase robust growth, with revenue climbing 25% year-over-year to $3.0 billion. The company credits accelerating AI adoption for driving demand for its high-capacity nearline hard drives and advanced technologies like HAMR and UltraSMR.
As the wearables market surges, Biolinq CEO Richard Yang positions smart patches as the next evolution, capable of tracking deep biochemical data where watches track surface metrics, with his company's FDA-cleared glucose sensor leading the charge.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Hong Kong apparel giant Crystal International is investing in a high-tech logistics center in China, aiming to slash fabric transfer times by 75% and power operations with solar energy as part of its broader smart manufacturing push.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
Micron Technology's stock has skyrocketed over 360% in the past year, fueled by insatiable AI-driven demand for memory chips. But with shares now trading at a significant premium to some traditional valuation models, investors face a critical question: has the rally run too far, too fast?
Western Digital leverages strong quarterly results and new customer deals to outline its long-term AI storage strategy at its Innovation Day event, as investors weigh its positioning in the booming data infrastructure market.
Precious metals markets experienced one of their most volatile weeks on record, with silver plummeting 26% and gold dropping 9% in a dramatic reversal. The sell-off, triggered by shifting U.S. policy expectations, laid bare the market's recent dependence on speculative flows from China, raising questions about stability ahead of the Lunar New Year.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.
The U.S. dollar staged a sharp rally Friday, while gold and silver prices plunged, following President Trump's nomination of former Fed Governor Kevin Warsh to lead the central bank. The move, interpreted as a hawkish signal for monetary policy, combined with strong economic data to reshape market expectations.
Oracle's deepening role as TikTok's U.S. data guardian and its aggressive push into regulated AI sectors present a dual narrative of strategic growth and heightened operational scrutiny, following a service outage linked to its infrastructure.
While investors chase AI's headline names, optical networking leader Ciena has quietly outperformed the sector. With surging demand for high-speed data transmission and an attractive valuation, it presents a compelling case for the coming year.
